• News
  • North America

Marrow Therapeutics Launches With $173 Million in Funding

Watertown biotech develops bone marrow-targeted genetic medicines for blood disorders

11/17/2026
•Ghita Khalfaoui
Back to News

Marrow Therapeutics launched with a combined $173 million across Series A and Series B funding. The Watertown, Massachusetts company is developing bone marrow-targeted therapies for severe blood disorders. OrbiMed led the $120 million Series B, while Scion Life Sciences and venBio co-led the $53 million Series A.


Funding details

Existing Series A investors also joined the Series B. New funds included RTW Investments, Surveyor Capital, Opaleye, and NEXTBio Capital. Other new investors included Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.

Company leadership

Scion Life Sciences founded the company. Romesh Subramanian serves as President and Chief Executive Officer. Tim Weeden is Chief Scientific Officer, and John Najim is Chief Operating Officer and Chief Technology Officer.

How the platform works

The company's Transferrin Antibody Bioconjugate platform uses engineered antibodies against the transferrin receptor TfR1. These antibodies deliver therapeutic payloads directly to bone marrow cells. Its lead candidate, MAR-101, is designed to treat sickle cell disease and beta thalassemia by reducing BCL11a and reactivating fetal hemoglobin.


Marrow is advancing multiple programs with its TAB platform. MAR-101 remains in IND-enabling studies. The company plans to move its programs into the clinic in the coming year.